September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

CME Congresses .

September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

CME Congresses .

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

CME Congresses .

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?

CME Congresses .

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?

September 1st- Talquetamab at 3 Years: Durability, Safety, and the Future of Myeloma Sequencing

CME Congresses .

September 1st- Talquetamab at 3 Years: Durability, Safety, and the Future of Myeloma Sequencing

August 6th- Beyond the webinar- Preventing Relapse After Allogeneic Transplantation in High-Risk Myeloid Malignancies: Are We Entering the Era of Precision Post-Transplant Care?

CME Congresses .

August 6th- Beyond the webinar- Preventing Relapse After Allogeneic Transplantation in High-Risk Myeloid Malignancies: Are We Entering the Era of Precision Post-Transplant Care?

July 23rd- Beyond the webinar- EHA ASCO 2026 Highlights in AML and MDS

CME Congresses .

July 23rd- Beyond the webinar- EHA ASCO 2026 Highlights in AML and MDS

August 4th- Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

CME Congresses .

August 4th- Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

August 12th- The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)

CME Congresses .

August 12th- The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)

August 19th- Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis

CME Congresses .

August 19th- Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis